Credit: Unsplash/CC0 Public Domain
The new study by the University of Exeter, published in Cell Host Microbe, has cast new light on how to best combine antibiotics and phage therapy
New research has moved a step closer to harnessing viruses to fight bacterial infection, reducing the threat of antibiotic resistance.
A growing number of infections, including pneumonia, tuberculosis, gonorrhoea, and salmonellosis, are developing antibiotic resistance, which means they becoming harder to treat, resulting in higher death rates, longer hospital stays and higher costs.
Phage therapy is the concept of using viruses (known as phage) that are harmless to humans to kill bacteria. Phage therapy can be used in combination with antibiotics to cure infections more effectively, and reduce the opportunity for bacteria to develop antibiotic resistance. However, bacteria can also evolve resistance to phages.
The new study by the University of Exeter, published in Cell Host Microbe, has cast new light on how to best combine antibiotics and phage therapy. Researchers conducted laboratory experiments on Pseudomonas aeruginosa a bacterium which causes disease in immunocompromised and cystic fibrosis patients. They exposed the bacterium to eight types of antibiotics – and found differences in the mechanisms by which the bacteria evolve resistance to phages, which affect how harmful they are.
Viruses penetrate molecules on the cell surface to infect bacteria. Like the human immune system, bacteria have their own CRISPR defence system, made up of proteins that fight off infection. As in human immune responses, this means that the virus infects the bacteria, and is then killed. In the process, the bacteria’s CRISPR system learns to recognise and attack the virus in future.
However, the bacteria have a second defence option. They can also change their own cell surface to ward off infection, losing the receptor to which phages normally attach. This option comes with a cost to bacteria – the bacteria become less virulent, meaning they no longer cause disease, or the disease becomes less severe.
In the study, four of the eight antibiotics tested caused a dramatic increase in the levels of CRISPR-based immunity. These antibiotics are all bacteriostatic – they do not directly kill cells but act by slowing down cell growth.
Professor Edze Westra, of the University of Exeter, said; “Antibiotic resistance is a major public health issue, and we need to take swift and urgent action. Phage therapy could be an important part of the toolkit, in reducing antibiotic use, and in using them in combination to increase their efficiency. We found that by changing the type of antibiotics that are used in combination with phage, we can manipulate how bacteria evolve phage resistance, increasing the chances that treatment is effective. These effects should be considered during phage-antibiotic combination therapy, given their important consequences for pathogen virulence.”
Phage therapy was first used in 1919, when Parisian microbiologist Félix d’Hérelle gave a phage cocktail to a 12-year-old boy, apparently curing his severe dysentery. Yet despite early promise, research dried up in the 40s as the world began to adopt the quick medical fix of antibiotics.
Now, research is again gathering momentum as part of the solution to reduce antibiotic resistance. Although a promising alternative with some remarkable case studies of phage therapy working in individuals, one obstacle to wider use is that bacteria can rapidly evolve resistance to phages, via CRISPR-Cas immunity or via modification of their surface.
The researchers show that the effect of bacteriostatic antibiotics triggering CRISPR-Cas immunity results from slower phage replication inside the cell, which provides more time for the CRISPR-Cas system to acquire immunity and clear the phage infection. The research therefore identifies the speed of phage replication as a crucial factor controlling the possibility for CRISPR-Cas systems to defend against viruses.
Lead author Dr Tatiana Dimitiru, of the University of Exeter, said: This study provides fundamental insight into the constraints of CRISPR immune systems in the face of viruses. It was recently discovered that many CRISPR-Cas immune systems are associated to cell responses that make bacteria slow or stop growth upon phage infection, and we speculate that this may be important for cells to trigger an effective immune response.
Original Article: New research moves closer to harnessing viruses to fight bacteria and reduce antibiotic use
More from: University of Exeter
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Combining antibiotics and phage therapy
- Therapy to kill hypervirulent bacteria developed
A study has identified a therapy that can penetrate the slime that such infections use to protect themselves from antibiotics. Scientists showed that an antimicrobial peptide from cows has potential ...
- Medical school scientist creates therapy to kill hypervirulent bacteria
College of Medicine researcher Renee Fleeman is on a mission to kill drug-resistant bacteria, and her latest study has identified a therapy that can penetrate the slime that such infections use to ...
- Multisite QI collaborative increases appropriate pediatric antibiotic use
A multisite collaborative increases appropriate antibiotic use for pediatric community-acquired pneumonia, skin and soft tissue infections, and urinary tract infections, according to a study published ...
- Personalized 'cocktails' of antibiotics, probiotics and prebiotics hold promise in treating IBS, pilot study finds
Personalized "cocktails" of antibiotics, probiotics and prebiotics hold great promise in the treatment of a common form of irritable bowel syndrome (IBS), according to research presented at the ESCMID ...
- Scientists discover new phage resistance mechanism in phage-bacterial arms race
Scientists describe a new mechanism impacting the phage-bacterial arms race, a nanosized epibiotic parasite, TM7x, which helps its host bacterium (a Schaalia odontolytica strain called XH001) achieve ...
Go deeper with Google Headlines on:
Combining antibiotics and phage therapy
[google_news title=”” keyword=”combining antibiotics and phage therapy” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Phage therapy
- Cytophage To Focus On Commercialization Efforts In 2024
Cytophage Technologies (TSXV: CYTO) has filed its fiscal 2023 results, providing a recap on a successful year in terms of corporate development while providing an outline of where the company is ...
- Introducing Yesterday's Phage Therapy in Today's Medicine
Phage therapy – the use of the viruses of bacteria to fight bacterial infection – was first advocated by Felix d'Herelle in 1919. Due to the advent of antibiotics and scientific controversies ...
- Giant virus discovered in wastewater treatment plant infects deadly parasite
The single-celled organism Naegleria fowleri ranks among the deadliest human parasites. Researchers around Matthias Horn and Patrick Arthofer from the Center for Microbiology and Environmental Systems ...
- Phage Therapies for Multidrug-Resistant Infections Should Consider Host Response
Research has found that therapeutic phages can be detected by epithelial cells of the human respiratory tract and elicit an immune response. These findings suggest that human–host interactions should ...
- Be part of the conversation and shape the future of phage therapy
The 7th World Conference on Targeting Phage Therapy is being organized on June 20-21, 2024 at Corinthia Palace Malta with more than 20 international speakers. The 7 th World Conference on ...
Go deeper with Google Headlines on:
Phage therapy
[google_news title=”” keyword=”phage therapy” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]